Overview

Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed Conditions

Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Oxcarbazepine Suspension 600 mg under fed conditions
Phase:
Phase 1
Details
Lead Sponsor:
Roxane Laboratories
Treatments:
Carbamazepine
Oxcarbazepine